APA (7th ed.) Citation

R, N., LQ, C., EC, D., R, B., S, G., R, G., . . . L, B. (2016). Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(21), 2460. https://doi.org/10.1200/JCO.2015.64.8931

Chicago Style (17th ed.) Citation

R, Nanda, et al. "Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 34, no. 21 (2016): 2460. https://doi.org/10.1200/JCO.2015.64.8931.

MLA (9th ed.) Citation

R, Nanda, et al. "Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 34, no. 21, 2016, p. 2460, https://doi.org/10.1200/JCO.2015.64.8931.